National Practice Patterns and Outcomes for T4b Urothelial Cancer of the Bladder

被引:22
作者
Haque, Waqar [1 ]
Verma, Vivek [2 ]
Butler, E. Brian [3 ]
Teh, Bin S. [3 ]
机构
[1] Greater Houston Phys Med Assoc, Dept Radiat Oncol, Houston, TX USA
[2] Univ Nebraska Med Ctr, Dept Radiat Oncol, Omaha, NE USA
[3] Houston Methodist Hosp, Dept Radiat Oncol, Houston, TX 77030 USA
关键词
Bladder cancer; Chemoradiation; Chemotherapy; Cystectomy; Radiation therapy; RADICAL CYSTECTOMY; DATA-BASE; NEOADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTORS; SURVIVAL; CARCINOMA; CARE; THERAPY;
D O I
10.1016/j.clgc.2017.08.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The National Cancer Data Base was queried (2004-2013) for patients diagnosed with T4b bladder cancer. A total of 896 patients were observed. Patients treated with definitive chemoradiation or radical cystectomy were observed to have the highest overall survival. Purpose: Management of cT4b bladder cancer is poorly defined; national guidelines recommend chemotherapy (CT) alone or chemoradiation (CRT). Using a large, contemporary dataset, we evaluated national practice patterns as well as associated outcomes, especially with respect to radical cystectomy (RC) and CRT versus CT alone. Methods: The National Cancer Data Base was queried (2004-2013) for patients diagnosed with cT4bN0-3M0 bladder cancer. Patients were divided into 5 treatment groups: CT alone, CRT, RC (with/without CT/radiotherapy [RT]), other treatment (subtherapeutic RT with/without CT), or no treatment. Statistics included multivariable logistic regression to determine factors predictive of observation, Kaplan-Meier analysis to evaluate overall survival (OS), and Cox proportional hazards modeling to determine variables associated with OS. Results: Of 896 total patients, 185 (20.6%) underwent CT alone, 80 (8.9%) CRT, 161 (18.9%) RC, 221 (24.7%) other treatments, and 249 (27.8%) observation. Differences in treatment paradigms were appreciated based on age, gender, nodal status, insurance, and facility-related parameters. Observation yielded a median OS of 3.7 months, lower than CT alone (P < .001). As compared with the latter, CRT was associated with higher OS (10.5 vs. 12.1 months, P = .004). RC-based treatment displayed the numerically highest OS (14.2 months) and was statistically similar to CRT (P = .676). Treatment with any modality independently predicted for superior OS over observation. Conclusions: In the largest study of its kind, a surprisingly high proportion of patients underwent observation. CRT is associated with higher survival over CT alone, and carefully selected patients undergoing RC may experience prolonged survival. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:42 / +
页数:9
相关论文
共 21 条
[1]   Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: Focus on supplementary treatment strategies [J].
Als, Anne Birgitte ;
Sengelov, Lisa ;
von der Maase, Hans .
EUROPEAN UROLOGY, 2007, 52 (02) :478-487
[2]   The National Cancer Data Base: A powerful initiative to improve cancer care in the United States [J].
Bilimoria, Karl Y. ;
Stewart, Andrew K. ;
Winchester, David P. ;
Ko, Clifford Y. .
ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (03) :683-690
[3]   The role of radical cystectomy in patients with clinical T4b bladder cancer [J].
Black, Peter C. ;
Dinney, Colin P. N. ;
Brown, Gordon A. ;
Kassouf, Wassim ;
Siefker-Radtke, Arlene O. ;
Munsell, Mark F. ;
Grossman, H. Barton ;
Kamat, Ashish M. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (02) :157-161
[4]  
Cheng L, 2000, CANCER-AM CANCER SOC, V88, P2326, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2326::AID-CNCR17>3.0.CO
[5]  
2-T
[6]  
Cheon Jaewoo, 2010, Korean J Urol, V51, P525, DOI 10.4111/kju.2010.51.8.525
[7]   Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties [J].
Choueiri, Toni K. ;
Raghavan, Derek .
NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (08) :444-454
[8]   Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes [J].
Dobruch, Jakub ;
Daneshmand, Siamak ;
Fisch, Margit ;
Lotan, Yair ;
Noon, Aidan P. ;
Resnick, Matthew J. ;
Shariat, Shahrokh F. ;
Zlotta, Alexandre R. ;
Boorjian, Stephen A. .
EUROPEAN UROLOGY, 2016, 69 (02) :300-310
[9]   Impact of gender on bladder cancer incidence, staging, and prognosis [J].
Fajkovic, Harun ;
Halpern, Joshua A. ;
Cha, Eugene K. ;
Bahadori, Atessa ;
Chromecki, Thomas F. ;
Karakiewicz, Pierre I. ;
Breinl, Eckart ;
Merseburger, Axel S. ;
Shariat, Shahrokh F. .
WORLD JOURNAL OF UROLOGY, 2011, 29 (04) :457-463
[10]   Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [J].
Grossman, HB ;
Natale, RB ;
Tangen, CM ;
Speights, VO ;
Vogelzang, NJ ;
Trump, DL ;
White, RWD ;
Sarosdy, MF ;
Wood, DP ;
Raghavan, D ;
Crawford, ED .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (09) :859-866